Bristol-Myers Squibb BMY Other revenue — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's other revenue — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's other revenue — total revenues?
- Bristol-Myers Squibb (BMY) reported other revenue — total revenues of -$15M in Q1 2026.
- What does other revenue — total revenues mean?
- Revenue derived from non-core business activities and financial hedging instruments that is not generated by primary pharmaceutical product sales.
- How do you interpret other revenue — total revenues?
- An increase may indicate successful financial hedging or growth in secondary business lines, while a decrease suggests reduced non-core income or unfavorable hedging outcomes.
- How does other revenue — total revenues compare across companies?
- Peers often report this as 'Other Revenue' or 'Miscellaneous Income,' though the composition varies significantly based on the firm's hedging strategy and non-core asset portfolio.